|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.06 EUR | -0.88% |
|
+2.42% | +7.38% |
| Dec. 10 | Medincell Narrows Operating Loss in First Half |  |
| Dec. 10 | MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Conducting Research and Development on Biodegradable Polymer-Based Processes | 11.78M | 4.09M | 13.66M | 11.94M | 27.73M | |||||
Total Assets | 63.61M | 44.3M | 29.34M | 36.95M | 90.45M | |||||
Interest Expense | -3.58M | -1.84M | -3.93M | -4.62M | -5.09M | |||||
Income Tax Expense | - | - | - | 88K | 160K | |||||
CAPEX | -819K | -1.97M | -576K | -324K | -747K | |||||
EBT | -19.02M | -24.81M | -32.01M | -24.95M | -18.28M | |||||
D&A | 1.14M | 1.36M | 1.5M | 1.52M | 1.38M | |||||
Operating Income | -15.61M | -23.81M | -24.05M | -20.98M | -10.84M | |||||
Net Income | -19.02M | -24.81M | -32.01M | -25.04M | -18.44M |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Germany | - | 368K | 1.98M | - | - | |||||
Others | 1.11M | - | 2.57M | 1.35M | - | |||||
Switzerland | - | 1.31M | - | 632K | - | |||||
United States | 2.54M | 2.41M | 2.18M | 1.63M | - | |||||
Israel | 4.35M | - | 3.16M | 5.42M | - | |||||
France | 200K | - | - | - | - |
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
